Still More To Be Done On European Biosimilars

Off-patent industry association Medicines for Europe has released a Biosimilar Market Review report that examines availability, pricing systems, retail markets, hospital tendering, reimbursement systems, healthcare practitioner-related policies, information and education around biosimilars in 26 European countries, concluding that “while progress has been made, it is clear much more can be done.”